BIOLASE (BIOL) Diolase 10 Cleared by FDA for Use in Additional Markets
BIOLASE, Inc. (NASDAQ: BIOL) announced today that the U.S. Food and Drug Administration (FDA) has cleared the 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. This FDA clearance includes over 80 different procedures.
You May Also Be Interested In
- BIOLASE Announces That Non-Executive Board Member Federico Pignatelli Has Withdrawn His Lawsuit against Company
- Roth Boosts PT on Regeneron (REGN) to $399 Following ODYSSEY Phase III Data, EYLEA Approval
- Halozyme Therapeutics (HALO) drug has favorably benefits versus risk, FDA Panel said (halted)
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!